$-0.23 EPS Expected for ESSA Pharma Inc (EPI)

November 25, 2017 – By Max Morgan

Investors wait ESSA Pharma Inc (TSE:EPI) to report on December, 13. its quarterly earnings Wall Street analysts expect $-0.23 EPS, down $0.03 or 15.00 % from last year’s $-0.2 same quarter earnings. ESSA Pharma Inc’s Wall Street analysts see 4.55 % negative EPS growth, taking into account the $-0.22 EPS reproted in the previous quarter, The stock increased 5.97% or $0.02 on November 24, reaching $0.355. About 45,800 shares traded or 9.29% up from the average. ESSA Pharma Inc (TSE:EPI) has 0.00% since November 25, 2016 and is . It has underperformed by 16.70% the S&P500.

ESSA Pharma Inc. is a Canada-based clinical-stage development pharmaceutical company. The company has market cap of $10.35 million. The Firm is focused on the development of small molecule drugs for the treatment of castration-resistant prostate cancer . It currently has negative earnings. The Firm is developing drugs, which selectively block the amino-terminal domain (NTD) of the androgen receptor (AR).

More notable recent ESSA Pharma Inc (TSE:EPI) news were published by: Prnewswire.com which released: “ESSA Pharma Announces Closing of US$15 Million Private Placement” on January 14, 2016, also Seekingalpha.com with their article: “ESSA Pharma continues slide; shares down 36%” published on June 06, 2017, Quotes.Wsj.com published: “Essa Pharma Inc.” on February 14, 2011. More interesting news about ESSA Pharma Inc (TSE:EPI) were released by: Seekingalpha.com and their article: “Essa Pharma Is More Likely To Fly Than To Die” published on September 06, 2017 as well as Prnewswire.com‘s news article titled: “ESSA Pharma Inc. Receives FDA Approval to Commence Clinical Development” with publication date: September 23, 2015.